MPSlabs

Enhancing the predictive power of Microphysiological Systems (MPS) and Organ-on-Chips (OoCs) in drug testing through advanced software solutions and consulting services.

About the Program

MPSlabs, a dedicated business unit of ESQlabs, develops software solutions and provides consulting services for pharmaceutical companies and research institutions working with microphysiological systems and organ-on-chips. Our mission is to enhance the predictive power of MPS and OoCs in drug testing by:

  • Emulating human physiological conditions
  • Translating results to in-human situations
  • Assessing drug efficacy
  • Early identification of potential hazards

Key Services

Our platform is built on three main pillars:

  • Multi-functional Scaling: Optimization of MPS and OoC system morphology and geometry for accurate replication of human physiology in vitro

  • Experimental Design and Operation: Tailored protocol design services for precise experiment setup and modeling of complex biological processes

  • Integration with ESQlabs Core: Seamless incorporation of MPS and OoC data into ESQlabs core services for enhanced translational and predictive accuracy

Recent Achievements

The program has established significant collaborations with industry leaders:

  • Partnership with Bayer for reducing animal testing in consumer health industry
  • Collaboration with Sanofi in advancing organ-on-chip technology
  • Secured €2.5M EIC Grant for technology validation with international end-users

Impact

Our solutions support: - Reduction of animal testing in pharmaceutical research - Enhanced drug development efficiency - More accurate prediction of drug behavior - Accelerated path to clinical success

The program continues to expand its partnerships and capabilities, working with leading pharmaceutical companies and research institutions worldwide.